Dose Denied: How Big Pharma's Patent Games Are Leaving Canadians Without the Medications They Need

Canada likes to tell itself a particular story about healthcare. It is a story of universality, of a social contract that promises no Canadian will be left to suffer simply because they cannot afford to see a doctor. It is a story worth telling. It is also, when it comes to prescription drugs, profoundly incomplete.

While physician visits and hospital stays fall under the protection of the Canada Health Act, prescription medications largely do not. That gap — deliberate, contested, and enormously profitable for certain parties — has quietly transformed into one of the most consequential fault lines in Canadian public health. And the corporations that benefit from it have spent decades ensuring it stays exactly where it is.

The Patent Evergreening Trap

At the centre of Canada's drug pricing crisis sits a practice known as "evergreening" — a strategy pharmaceutical giants use to extend monopoly control over a drug long past its original patent expiry. By making minor, often clinically insignificant modifications to an existing medication — a new coating, a slightly altered dosage schedule, a different delivery mechanism — corporations can file fresh patents and block the entry of cheaper generic alternatives for years, sometimes decades.

Canada's patent linkage regulations, introduced under pressure from American trade negotiators, have made this process easier than it should be. Under the current framework, brand-name manufacturers can challenge generic competitors through a legal mechanism that automatically delays approval of lower-cost alternatives while litigation proceeds. The result is a system that incentivises pharmaceutical companies to litigate rather than innovate — and that hands them the time they need to extract maximum revenue before competition arrives.

The Patented Medicine Prices Review Board (PMPRB) was designed, in theory, to act as a counterweight. Recent reforms attempted to expand the basket of comparator countries used to benchmark Canadian drug prices and to introduce a pharmaco-economic analysis that accounts for therapeutic value. The pharmaceutical industry responded with aggressive lobbying and legal challenges that delayed implementation for years. The reforms that eventually survived were significantly watered down.

Rationing Insulin in a Rich Country

The human consequences of this system are not abstract. Consider the case of Canadians living with Type 1 diabetes who rely on newer analogue insulins — medications that offer superior glycaemic control and reduced risk of dangerous hypoglycaemic episodes compared to older formulations. In provinces without comprehensive formulary coverage for these drugs, many patients face out-of-pocket costs that can exceed one thousand dollars per month.

For those without employer-sponsored drug benefits — disproportionately low-income workers, the self-employed, and those in precarious employment — the arithmetic is brutal. Rationing insulin: stretching doses, skipping injections, or reverting to older, less effective formulations, is not a fringe behaviour. Canadian diabetes advocacy organisations have documented it extensively. It is a rational response to an irrational system.

The same calculus applies to oncology. Cancer patients in Canada face a deeply inequitable patchwork of drug coverage depending on which province they happen to live in, whether their cancer is treated in a hospital or outpatient setting, and whether their specific drug has been approved by the Canadian Drug Review and subsequently listed on provincial formularies. Drugs that have been approved by Health Canada — meaning regulators have determined they are safe and effective — can sit in a bureaucratic queue for years before public coverage is extended. During that time, patients either pay privately, access compassionate use programmes at the discretion of manufacturers, or go without.

Supply Manipulation and Manufactured Scarcity

Beyond pricing strategy, pharmaceutical corporations have demonstrated a willingness to manipulate supply in ways that serve their commercial interests. Drug shortages in Canada have become chronic and, critics argue, predictably convenient. When a generic competitor is poised to enter the market, shortages of the brand-name product can create conditions that push patients and prescribers toward newer, still-patented alternatives rather than simply waiting for the cheaper option.

Health Canada maintains a drug shortage database, and the numbers are striking. In any given year, hundreds of medications are listed as experiencing supply disruptions. The causes are varied — global supply chain vulnerabilities, manufacturing consolidation, raw material shortages — but the pattern of who benefits from scarcity and who bears its costs is remarkably consistent. Patients and public insurers absorb the financial and health burdens. Manufacturers protect their margins.

The National Pharmacare Delay

The federal government's long-promised national pharmacare programme represents the most significant structural opportunity to rebalance this equation. A universal, single-payer drug plan would give Canada the purchasing power to negotiate drug prices from a position of collective strength — the same leverage that allows countries like New Zealand and the Netherlands to pay a fraction of what Canadians pay for identical medications.

Yet despite years of advocacy, a landmark advisory council report, and explicit commitments from successive governments, implementation has proceeded at a pace that can only be described as glacial. The pharmaceutical industry has not been passive during this delay. Lobbying expenditures by brand-name drug manufacturers in Canada run into the tens of millions of dollars annually. The industry has cultivated relationships across party lines, funded patient advocacy organisations, and shaped public debate in ways that position universal drug coverage as a threat to innovation rather than a fulfilment of the healthcare promise Canadians were already supposed to have.

Who the System Was Built For

It is worth being direct about what Canada's current drug access regime represents: a policy architecture that was built, and is continuously maintained, to serve the commercial interests of a small number of extraordinarily profitable corporations. The patents, the trade agreements, the regulatory delays, the provincial formulary fragmentation — none of these features are accidents. They are the accumulated product of decades of industry influence over the rules that govern access to medicine.

Canadians who ration their medications are not experiencing a failure of healthcare. They are experiencing the intended operation of a system designed to extract maximum revenue before ceding ground to cheaper alternatives or public purchasing power. That this occurs within a country that officially endorses universal healthcare is not a paradox — it is a policy choice, made repeatedly, on behalf of interests that are not the public's.

Holding that reality clearly in view is the first step toward demanding something better.